SCHEMBL5544724

SCHEMBL5544724

[CH2]CC(=O)Nc1ccc(C(F)(F)C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MLYCD O95822 2/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TGM2 P21980 1/20 0.44
RORC P51449 4/20 0.43
KCNJ5 P48544 1/20 0.42
KCNJ3 P48549 1/20 0.42
PDK1 Q15118 1/20 0.41
PDK2 Q15119 1/20 0.41
PDK3 Q15120 1/20 0.41
PDK4 Q16654 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535788 0.87 MLYCD (0.49) EPHX2L3MBTL1MLYCDMEN1KMT2A
SCHEMBL5541440 0.86 EPHX2 (0.63) EPHX2L3MBTL1MEN1KMT2AHTT
SCHEMBL9728270 0.84 EPHX2 (0.47) EPHX2L3MBTL1MLYCDMEN1KMT2A
SCHEMBL5544063 0.81 MAPT (0.55) L3MBTL1MEN1KMT2AHTTNPSR1
SCHEMBL5544650 0.80 EPHX2 (0.50) EPHX2MEN1KMT2AHTTSMN1; SMN2
SCHEMBL6693774 0.80 TP53 (0.62) MLYCDMEN1KMT2AHTTSMN1; SMN2
SCHEMBL2090357 0.79 SMN1; SMN2 (0.45) EPHX2L3MBTL1MLYCDMEN1KMT2A
SCHEMBL2096237 0.78 EPHX2 (0.52) EPHX2L3MBTL1SMN1; SMN2TGM2RORC
SCHEMBL2096233 0.78 EPHX2 (0.52) EPHX2MEN1KMT2AHTTSMN1; SMN2
SCHEMBL20560559 0.77 EPHX2 (0.50) EPHX2HTTSMN1; SMN2TGM2RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 EPHX2 3662/4885L3MBTL1 1931/4885MLYCD 1955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.